Effectiveness of Docetaxel for Metastatic Hormone-sensitive Prostate Cancer in Clinical Practice

Dy, 2017, Global burden of urologic cancers, 1990–2013, Eur Urol, 71, 437, 10.1016/j.eururo.2016.10.008 Siegel, 2017, Cancer statistics, 2017, CA Cancer J Clin, 67, 7, 10.3322/caac.21387 Helgstrand, 2018, Trends in incidence and 5-year mortality in men with newly diagnosed, metastatic prostate cancer—a population-based analysis of 2 national cohorts, Cancer, 124, 2931, 10.1002/cncr.31384 Huggins, 2002, Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941, J Urol, 168, 9, 10.1016/S0022-5347(05)64820-3 Prostate Cancer Trialists’ Collaborative Group, 2000, Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials, Lancet, 355, 1491, 10.1016/S0140-6736(00)02163-2 Gravis, 2013, Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial, Lancet Oncol, 14, 149, 10.1016/S1470-2045(12)70560-0 Sweeney, 2015, Chemohormonal therapy in metastatic hormone-sensitive prostate cancer, N Engl J Med, 373, 737, 10.1056/NEJMoa1503747 James, 2016, Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial, Lancet (London, England), 387, 1163, 10.1016/S0140-6736(15)01037-5 Tucci, 2016, Addition of docetaxel to androgen deprivation therapy for patients with hormone-sensitive metastatic prostate cancer: a systematic review and meta-analysis, Eur Urol, 69, 563, 10.1016/j.eururo.2015.09.013 Mottet, 2018, Updated guidelines for metastatic hormone-sensitive prostate cancer: abiraterone acetate combined with castration is another standard, Eur Urol, 73, 316, 10.1016/j.eururo.2017.09.029 Anand, 2017, Translating Prostate Cancer Working Group 2 (PCWG2) progression criteria into a quantitative response biomarker in metastatic castration-resistant prostate cancer (mCRPC), J Clin Oncol, 35, 170, 10.1200/JCO.2017.35.6_suppl.170 Sargent, 2010, What constitutes reasonable evidence of efficacy and effectiveness to guide oncology treatment decisions?, Oncologist, 15, 19, 10.1634/theoncologist.2010-S1-19 Glasser, 2007, Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems, J Clin Pharmacol, 47, 1074, 10.1177/0091270007304776 Djulbegovic, 2011, From efficacy to effectiveness in the face of uncertainty: indication creep and prevention creep, JAMA, 305, 2005, 10.1001/jama.2011.650 Kyriakopoulos, 2018, Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial, J Clin Oncol, 36, 1080, 10.1200/JCO.2017.75.3657 Gravis, 2016, Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial, Eur Urol, 70, 256, 10.1016/j.eururo.2015.11.005 Clarke, 2019, Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial, Ann Oncol, 30, 1992, 10.1093/annonc/mdz396 Vale, 2016, Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data, Lancet Oncol, 17, 243, 10.1016/S1470-2045(15)00489-1 Wu, 2014, No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period, Cancer, 120, 818, 10.1002/cncr.28485 Francini, 2018, Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC), Prostate, 78, 889, 10.1002/pros.23645 Gravis, 2018, Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG-AFU15 studies, Eur Urol, 73, 847, 10.1016/j.eururo.2018.02.001 Hussain, 2006, Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162), J Clin Oncol, 24, 3984, 10.1200/JCO.2006.06.4246 Glass, 2003, Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning, J Urol, 169, 164, 10.1016/S0022-5347(05)64059-1 Gillessen, 2020, Management of patients with advanced prostate cancer: report of the Advanced Prostate Cancer Consensus Conference 2019, Eur Urol, 77, 508, 10.1016/j.eururo.2020.01.012 Mohler, 2019, Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology, J Natl Compr Canc Netw, 17, 479, 10.6004/jnccn.2019.0023 Lavoie, 2019, Clinical effectiveness of docetaxel for castration-sensitive prostate cancer in a real-world population-based analysis, Prostate, 79, 281, 10.1002/pros.23733 Weiner, 2020, Survival following upfront chemotherapy for treatment-naïve metastatic prostate cancer: a real-world retrospective cohort study, Prostate Cancer Prostatic Dis, 10.1038/s41391-020-00278-0 Fizazi, 2017, Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer, N Engl J Med, 377, 352, 10.1056/NEJMoa1704174 James, 2017, Abiraterone for prostate cancer not previously treated with hormone therapy, N Engl J Med, 377, 338, 10.1056/NEJMoa1702900 Rydzewska, 2017, Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis, Eur J Cancer, 84, 88, 10.1016/j.ejca.2017.07.003 Vale, 2018, What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis, Ann Oncol, 29, 1249, 10.1093/annonc/mdy071 Armstrong, 2019, ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer, J Clin Oncol, 37, 2974, 10.1200/JCO.19.00799 Chi, 2019, Apalutamide for metastatic, castration-sensitive prostate cancer, N Engl J Med, 381, 13, 10.1056/NEJMoa1903307